L.F. de Geus-Oei
33 records found
1
Prostate-specific membrane antigen (PSMA) expression has been observed in a subset of soft tissue sarcomas, mainly in the neovascular endothelial cells. This feasibility study aimed to evaluate PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma, ...
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated with survival and treatment response.
Methods
Sixty mCRPC p ...
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies
Systematic literature review and meta-analysis
Artificial Intelligence as a New Research Ally?
Performing AI-Assisted Systematic Literature Reviews in Health Economics
The value of integrating clinical variables, radiomics, and tumor-derived cell-free DNA (cfDNA) for the prediction of survival and response to chemoradiation of patients with resectable esophageal adenocarcinoma is not yet known. Our aim was to investigate if radiomic ...
Selecting Targets for Molecular Imaging of Gastric Cancer
An Immunohistochemical Evaluation
Tumor-targeted positron emission tomography (PET) and fluorescence-guided surgery (FGS) could address current challenges in pre- and intraoperative imaging of gastric cancer. Adequate selection of molecular imaging targets remains crucial for successful tumor visualiz ...
Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients
A dose-finding study (HORA EST HCC trial)
This systematic literature review addresses model-based cost-effectiveness studies for therapy response monitoring with positron emission tomography (PET) generally combined with low-dose computed tomography (CT) for various cancer types. Given the kn ...
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer
(endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type
Literature review and comparison between guidelines
The recently released EANM/SNMMI guideline, endorsed by several important clinical and imaging societies in the field of breast cancer (BC) care (ACR, ESSO, ESTRO, EUSOBI/ESR, EUSOMA), emphasized the role of [18F]FDG PET/CT in management of patients with no special ty ...
Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, maligna ...
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer
Differences and agreements with European and American guidelines
In metastatic castration-resistant prostate cancer (mCRPC), using serum prostate-specific antigen (PSA) levels to evaluate treatment response is not always accurate. This study aimed to assess the efficacy of PSMA PET/CT at specific time points for evaluating treat ...